A citation-based method for searching scientific literature

David G Parkes, Kenneth F Mace, Michael E Trautmann. Expert Opin Drug Discov 2013
Times Cited: 54







List of co-cited articles
491 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Ann E Kingsbury, Christopher S Biggs, Peter S Whitton. J Neuroinflammation 2008
181
16

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
292
16


Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
260
14


Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
TracyAnn Perry, Norman J Haughey, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
252
12

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
759
11


A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
TracyAnn Perry, Debomoy K Lahiri, Demao Chen, Jie Zhou, Karen T Y Shaw, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
224
11

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
147
11

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
229
11



No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
K Tatarkiewicz, P Belanger, G Gu, D Parkes, D Roy. Diabetes Obes Metab 2013
40
12

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.
Niels Vrang, Jacob Jelsing, Lotte Simonsen, Andres Eskjær Jensen, Inger Thorup, Henrik Søeborg, Lotte Bjerre Knudsen. Am J Physiol Endocrinol Metab 2012
65
9

Incretin-based therapies for type 2 diabetes mellitus.
Julie A Lovshin, Daniel J Drucker. Nat Rev Endocrinol 2009
484
9


Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Mark S Fineman, K F Mace, M Diamant, T Darsow, B B Cirincione, T K Booker Porter, L A Kinninger, M E Trautmann. Diabetes Obes Metab 2012
105
9

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
727
9


Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Michael A Schwarzschild, Alberto Ascherio, M Flint Beal, Merit E Cudkowicz, Gary C Curhan, Joshua M Hare, D Craig Hooper, Karl D Kieburtz, Eric A Macklin, David Oakes,[...]. JAMA Neurol 2014
149
9


GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
383
9


Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.
Benjamin J Lamont, Yazhou Li, Edwin Kwan, Theodore J Brown, Herbert Gaisano, Daniel J Drucker. J Clin Invest 2012
116
7

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Laurie L Baggio, Qingling Huang, Xiemin Cao, Daniel J Drucker. Gastroenterology 2008
103
7



Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan P Weiner, Jeanne M Clark, Jodi B Segal. JAMA Intern Med 2013
260
7

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
Niels C B Nyborg, Anne-Marie Mølck, Lars W Madsen, Lotte Bjerre Knudsen. Diabetes 2012
104
7

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.
Krystyna Tatarkiewicz, Pamela A Smith, Emmanuel J Sablan, Clara J Polizzi, Donald E Aumann, Christiane Villescaz, Diane M Hargrove, Bronislava R Gedulin, Melissa G W Lu, Lisa Adams,[...]. Am J Physiol Endocrinol Metab 2010
77
7



Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
C M Mack, C X Moore, C M Jodka, S Bhavsar, J K Wilson, J A Hoyt, J L Roan, C Vu, K D Laugero, D G Parkes,[...]. Int J Obes (Lond) 2006
106
7



Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Orville G Kolterman, Dennis D Kim, Larry Shen, James A Ruggles, Loretta L Nielsen, Mark S Fineman, Alain D Baron. Am J Health Syst Pharm 2005
299
7

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
7


Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Mark L Wahlqvist, Meei-Shyuan Lee, Chih-Cheng Hsu, Shao-Yuan Chuang, Jiunn-Tay Lee, Hsin-Ni Tsai. Parkinsonism Relat Disord 2012
127
7

Urate as a predictor of the rate of clinical decline in Parkinson disease.
Alberto Ascherio, Peter A LeWitt, Kui Xu, Shirley Eberly, Arthur Watts, Wayne R Matson, Connie Marras, Karl Kieburtz, Alice Rudolph, Mikhail B Bogdanov,[...]. Arch Neurol 2009
237
7

Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4.
Song Chen, Ai-ran Liu, Feng-mao An, Wen-bing Yao, Xiang-dong Gao. Age (Dordr) 2012
86
7




The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem.
Elvira Alvarez, M Dolores Martínez, Isabel Roncero, Julie A Chowen, Beatriz García-Cuartero, Juan D Gispert, Carmen Sanz, Patricia Vázquez, Antonio Maldonado, Javier de Cáceres,[...]. J Neurochem 2005
167
7

Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
YiMei Chen, Yanfang Zhang, Lin Li, Christian Hölscher. Eur J Pharmacol 2015
58
7

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
314
7


Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines.
Filip Ventorp, Cecilie Bay-Richter, Analise Sauro Nagendra, Shorena Janelidze, Viktor Sjödahl Matsson, Jack Lipton, Ulrika Nordström, Åsa Westrin, Patrik Brundin, Lena Brundin. J Parkinsons Dis 2017
22
18


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.